Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting

Basit Öğe Kaydı
dc.contributor.authorYagdi, T
dc.contributor.authorNalbantgil, S
dc.contributor.authorAyik, F
dc.contributor.authorApaydin, A
dc.contributor.authorIslamoglu, F
dc.contributor.authorPosacioglu, H
dc.contributor.authorCalkavur, T
dc.contributor.authorAtay, Y
dc.contributor.authorBuket, S
dc.date.accessioned2019-10-27T19:00:24Z
dc.date.available2019-10-27T19:00:24Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: The purpose of this study was to evaluate the safety and efficacy of postoperative administration of prophylactic amiodarone in the prevention of new-onset postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Methods: In this prospective study 157 patients were randomly divided into two groups: 77 patients (amiodarone group) received intravenous amiodarone in a dose of 10 mg/kg/d for postoperative 48 hours. On postoperative day 2 oral amiodarone was started with a dose of 600 mg/d for 5 days, 400 mg/d for the following 5 days, and 200 mg/d for 20 days, and 80 patients received placebo (control group). Results: Preoperative patient characteristics and operative variables were similar in the two groups. Postoperative atrial fibrillation occurred in 8 patients (10.4%) receiving amiodarone and in 20 (25.0%) patients receiving placebo (P = .017). Duration of atrial fibrillation was 12.8 +/- 4.8 hours for the amiodarone group compared with 34.7 +/- 28.7 hours for the control group (P = .003). The maximum ventricular rate during atrial fibrillation was slower in the amiodarone group than in the control group (105.9 +/- 19.1 beats per minute and 126.0 +/- 18.5 beats per minute, respectively, P = .016). The two groups had a similar incidence of complication other than rhythm disturbances (20.8% vs 20.0%, P = .904). Amiodarone group patients had shorter hospital stays than that of control group patients (6.8 +/- 1.7 days vs 7.8 +/- 2.9 days, P = .014). The in-hospital mortality was not different between two groups (1.3% vs 3.8, P = .620). Conclusions: Postoperative intravenous amiodarone, followed by oral amiodarone, appears to be effective in the prevention of new-onset postoperative atrial fibrillation. It also reduces ventricular rate and duration of atrial fibrillation after coronary artery bypass grafting. It is well tolerated and decreases the length of hospital stay.en_US
dc.identifier.doi10.1016/S0022-5223(02)73292-3en_US
dc.identifier.endpage1425en_US
dc.identifier.issn0022-5223
dc.identifier.issue6en_US
dc.identifier.pmid12830063en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1420en_US
dc.identifier.urihttps://doi.org/10.1016/S0022-5223(02)73292-3
dc.identifier.urihttps://hdl.handle.net/11454/37776
dc.identifier.volume125en_US
dc.identifier.wosWOS:000183864700031en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMosby, Incen_US
dc.relation.ispartofJournal of Thoracic and Cardiovascular Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAmiodarone reduces the incidence of atrial fibrillation after coronary artery bypass graftingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu